Trial of Cytisine in Adult Smokers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-13

Study Completion Date

2019-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949

Smoking Cessation

COMPLETED PHASE3

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

NCT05431387

Vaping E-Cig Use

COMPLETED PHASE2

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT05206370

Smoking Cessation

COMPLETED PHASE3

A Single Dose-escalation Study of Cytisine in Adult Smokers

NCT03848208

Smoking Cessation

COMPLETED PHASE1

A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine

NCT03268343

Smoking Cessation

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.5 mg Cytisine, Commercial Schedule

1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support

Group Type EXPERIMENTAL

Cytisine

Intervention Type DRUG

film coated tablet containing 1.5 mg cytisine in a single tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

3.0 mg Cytisine, Commercial Schedule

3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support

Group Type EXPERIMENTAL

Cytisine

Intervention Type DRUG

film coated tablet containing 1.5 mg cytisine in a single tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Placebo, Commercial Schedule

Placebo tablets using the commercial 25-day titration schedule + behavioral support

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

1.5 mg cellulose powder to match final weight of the cytisine tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

1.5 mg Cytisine, TID Schedule

1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support

Group Type EXPERIMENTAL

Cytisine

Intervention Type DRUG

film coated tablet containing 1.5 mg cytisine in a single tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

3.0 mg Cytisine, TID Schedule

3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support

Group Type EXPERIMENTAL

Cytisine

Intervention Type DRUG

film coated tablet containing 1.5 mg cytisine in a single tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Placebo, TID Schedule

Placebo tablets for 25 days using a simplified TID schedule + behavioral support

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

1.5 mg cellulose powder to match final weight of the cytisine tablet

Behavioral support

Intervention Type BEHAVIORAL

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytisine

film coated tablet containing 1.5 mg cytisine in a single tablet

Intervention Type DRUG

Placebo Comparator

1.5 mg cellulose powder to match final weight of the cytisine tablet

Intervention Type DRUG

Behavioral support

12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects, age ≥ 18 years.
2. Current daily cigarette smokers (averaging ≥ 10 cigarettes per day upon completing a 7-day screening diary) and who intend to quit smoking.
3. Expired air carbon monoxide (CO) ≥ 10 parts per million (ppm).
4. Failed at least one previous attempt to stop smoking with or without therapeutic support.
5. Willing to initiate study treatment on the day after randomization and set a quit date that is 5-7 days after starting treatment.
6. Willing to actively participate in the study's smoking cessation behavioral support provided throughout the study.
7. Able to fully understand all study requirements, willing to participate, comply with dosing schedule, and sign the Informed Consent Form.

Exclusion Criteria

1. Known hypersensitivity to cytisine or any of the excipients.
2. Positive urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine.
3. Clinically significant abnormal serum chemistry or hematology values within 28 days of randomization (i.e. requiring treatment).
4. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).
5. Body mass index (BMI) classification for being underweight (\< 18.5 kg/m\^2) or having ≥ Class 2 obesity (≥ 35 kg/m\^2).
6. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
7. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).
8. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation (Suicide Behaviors Questionnaire-Revised \[SBQ-R\] score ≥ 7); or current symptoms of moderate to severe depression (Hospital Anxiety and Depression Scale \[HADS\] score ≥ 11).
9. Renal impairment defined as a creatinine clearance (CrCl) \< 60 mL/min (estimated with the Cockroft-Gault equation) or hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.0 times the upper limit of normal (ULN).
10. Women who are pregnant or breast-feeding.
11. Male or Female subjects of child bearing potential who do not agree to use acceptable methods of birth control during the study treatment period.
12. Participation in a clinical study with an investigational drug within 4 weeks of randomization.
13. Treatment with other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy \[NRT\]) within 4 weeks of randomization or planned use of these other smoking cessation medications during the study.
14. Use within 2 weeks of randomization or planned use during the study of non-cigarette nicotine products (e-cigarettes, pipe tobacco, cigars, snuff, chewing tobacco, hookah) or marijuana vaping or smoking.
15. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No